Quarterly report · Q2

Period2023-04-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 45
MetricValuePeriodScopeSource row
Revenue¥1.1bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥3.0bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥1.6bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income−¥242m2023-04-01 → 2023-09-30Cons.Operating income
Operating income−¥90m2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥70m2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income−¥120m2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥70m2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥62m2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥70m2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥61m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥305m2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥69m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥61m2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥69m2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥8.4bnat 2023-09-30Cons.Assets
Total assets¥8.4bnat 2023-03-31Cons.Assets
Total assets¥8.8bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥664mat 2023-09-30Cons.Liabilities
Total liabilities¥781mat 2023-03-31Cons.Liabilities
Net assets / equity¥7.7bnat 2023-09-30Cons.Net assets
Net assets / equity¥7.6bnat 2023-03-31Cons.Net assets
Net assets / equity¥7.9bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥2.1bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥1.9bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥2.1bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥1.9bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥2.7bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥2.6bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥58m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥141m2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥61m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow¥46m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥541m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥483m2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥485m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥0.712023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-0.132023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-3.622022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥0.822022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥0.312022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio92.1%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio90.7%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio89.0%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment ordinary income2023-04-01 → 2023-09-30−¥214m
jpcrp040300-q2r_E27585-000Medical Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥122m
jpcrp040300-q2r_E27585-000Medical Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥122m
jpcrp040300-q2r_E27585-000Medical Businessreportable segmentsegment ordinary income2023-04-01 → 2023-09-30¥110m
jpcrp040300-q2r_E27585-000Research Support Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥1.0bn
jpcrp040300-q2r_E27585-000Research Support Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.0bn
jpcrp040300-q2r_E27585-000Research Support Businessreportable segmentsegment ordinary income2023-04-01 → 2023-09-30¥174m
—segment totalrevenue2023-04-01 → 2023-09-30¥1.1bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥1.1bn
—segment totalsegment ordinary income2023-04-01 → 2023-09-30¥284m
Reconciling Itemsreconcilingsegment ordinary income2022-04-01 → 2022-09-30−¥286m
jpcrp040300-q2r_E27585-000Medical Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥674m
jpcrp040300-q2r_E27585-000Medical Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥674m
jpcrp040300-q2r_E27585-000Medical Businessreportable segmentsegment ordinary income2022-04-01 → 2022-09-30¥222m
jpcrp040300-q2r_E27585-000Research Support Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥903m
jpcrp040300-q2r_E27585-000Research Support Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥903m
jpcrp040300-q2r_E27585-000Research Support Businessreportable segmentsegment ordinary income2022-04-01 → 2022-09-30¥134m
—segment totalrevenue2022-04-01 → 2022-09-30¥1.6bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥1.6bn
—segment totalsegment ordinary income2022-04-01 → 2022-09-30¥356m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 486
ItemContextValueUnit
Income taxes paid ope cfPrior1YTDDuration-2341000JPY
Income taxes paid ope cfCurrentYTDDuration-1880000JPY
Net cash provided by used in operating activitiesPrior1YTDDuration60524000JPY
Net cash provided by used in operating activitiesCurrentYTDDuration58231000JPY
Purchase of short term investment securities inv cfPrior1YTDDuration-2000000000JPY
Purchase of short term investment securities inv cfCurrentYTDDuration-1500000000JPY
Proceeds from redemption of securities inv cfPrior1YTDDuration2000000000JPY
Proceeds from redemption of securities inv cfCurrentYTDDuration3000000000JPY
Purchase of investment securities inv cfPrior1YTDDuration-500000000JPY
Purchase of investment securities inv cfCurrentYTDDuration-1509193000JPY
Proceeds from sales and redemption of investment securities inv cfPrior1YTDDuration42000000JPY
Proceeds from sales and redemption of investment securities inv cfCurrentYTDDuration103790000JPY
Purchase of property plant and equipment inv cfPrior1YTDDuration-66694000JPY
Purchase of property plant and equipment inv cfCurrentYTDDuration-31740000JPY
Purchase of intangible assets inv cfPrior1YTDDuration-9728000JPY
Purchase of intangible assets inv cfCurrentYTDDuration-15283000JPY
Other net inv cfPrior1YTDDuration-6078000JPY
Other net inv cfCurrentYTDDuration-1352000JPY
Net cash provided by used in investment activitiesPrior1YTDDuration-540501000JPY
Net cash provided by used in investment activitiesCurrentYTDDuration46220000JPY
Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cfPrior1YTDDuration564715000JPY
Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cfCurrentYTDDuration-JPY
Repayment of long term loans payable fin cfPrior1YTDDuration-80000000JPY
Repayment of long term loans payable fin cfCurrentYTDDuration-JPY
Other net fin cfPrior1YTDDuration-0JPY
Other net fin cfCurrentYTDDuration-JPY
Net cash provided by used in financing activitiesPrior1YTDDuration484715000JPY
Net cash provided by used in financing activitiesCurrentYTDDuration-JPY
Effect of exchange rate change on cash and cash equivalentsPrior1YTDDuration21476000JPY
Effect of exchange rate change on cash and cash equivalentsCurrentYTDDuration66358000JPY
Net increase decrease in cash and cash equivalentsPrior1YTDDuration26215000JPY
Net increase decrease in cash and cash equivalentsCurrentYTDDuration170810000JPY
Cash and cash equivalentsPrior2YearInstant2636976000JPY
Cash and cash equivalentsPrior1YearInstant1914569000JPY
Cash and cash equivalentsPrior1QuarterInstant2663192000JPY
Cash and cash equivalentsCurrentQuarterInstant2085379000JPY
Salaries and allowances sgaPrior1YTDDuration174746000JPY
Salaries and allowances sgaCurrentYTDDuration215824000JPY
Provision for bonuses sgaPrior1YTDDuration5462000JPY
Provision for bonuses sgaCurrentYTDDuration4576000JPY
Provision of allowance for doubtful accounts sgaPrior1YTDDuration308000JPY
Provision of allowance for doubtful accounts sgaCurrentYTDDuration834000JPY
Compensations sgaPrior1YTDDuration45952000JPY
Compensations sgaCurrentYTDDuration76415000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E27585-000ResearchSupportBusinessReportableSegmentsMember902728000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q2r_E27585-000MedicalBusinessReportableSegmentsMember674028000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember1576757000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember-JPY
Revenues from external customersPrior1YTDDuration1576757000JPY
Net salesPrior1YTDDuration_jpcrp040300-q2r_E27585-000ResearchSupportBusinessReportableSegmentsMember902728000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass